Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma |
| |
| Authors: | Tamaru Jun-Ichi Tokuhira Michihide Nittsu Nozomi Nakamura Shigeo Ichinohasama Ryo Suzuki Ritsuro Mori Hiraki Takagi Toshiyuki Suzuki Takahiro Itami Jun Itoyama Shinji Mikata Atsuo |
| |
| Affiliation: | a Department of Pathology,b Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japanc Department of Hematology, Saitama Medical University, Iruma, Japand Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japane Department of Hematopathology, Tohoku University, School of Medicine, Sendai, Japanf Department of Hematopathology, Nagoya University, Nagoya, Japang Division of Hematology, Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japanh Department of Hematology and Chemotherapy, Chiba Cancer Center, Chiba, Japani Department of Pathology, St. Luke's International Hospital, Tokyo, Japanj Department of Radiology, National Medical Center, Tokyo, Japan |
| |
| Abstract: | In the WHO classification, the majority of Hodgkin-like ALCL cases as defined by the REAL classification are considered to be CHL. However, establishing a histological diagnosis for the gray zone between CHL and ALCL is often confusing. In this study, we re-evaluated such cases by performing immunohistochemistry with antibodies against PAX-5/BSAP, Oct.2, and BOB.1/OBF.1. Expression of PAX-5/BSAP was observed in 88% (76/87) of CHL specimens and none (0/11) of ALK-positive ALCL specimens. Among specimens of Hodgkin-like ALCL and ALK-negative ALCL, expression of PAX-5/BSAP was observed in 77% (20/26) and 18% (3/17), respectively. Most of the PAX-5/BSAP-positive specimens were negative for Oct.2 and/or BOB.1/OBF.1 except for four CHL specimens. Our results may support the WHO classification in which most cases of Hodgkin-like ALCL are classified as CHL. However, the patients with Hodgkin-like ALCL with CHL-immunophenotype (PAX-5/BSAP-positive and negative for Oct.2 and/or BOB.1) did not have a favorable outcome, with a 5-year OS rate of 58%. |
| |
| Keywords: | Hodgkin lymphoma anaplastic large cell lymphoma Hodgkin-like ALCL diffuse large B-cell lymphoma anaplastic variant PAX-5/BSAP Oct.2 BOB.1 cytotoxic molecule immunohistochemistry |
| 本文献已被 InformaWorld PubMed 等数据库收录！ |
|
